Prognostic Impact of 18-F-Florbetaben Amyloid PET Imaging in Patients with Isolated Increases in Cerebrospinal Fluid Phospho-Tau Biomarkers: A Longitudinal Study

J Alzheimers Dis. 2021;80(4):1389-1394. doi: 10.3233/JAD-201435.

Abstract

This longitudinal study evaluates the prognostic impact of amyloid PET in patients suspected of Alzheimer's disease and presenting with isolated cerebrospinal fluid (CSF) increases in P-Tau proteins (NCT02556502). The rate of conversion, based on the DSM-5 criteria and all collected data (average follow-up of 39.2±13.2 months), was determined by a panel of experts blinded to the PET results and was 75%(6/8) for positive and 35%(6/17) for negative baseline amyloid PET. In this population with isolated CSF increases in P-Tau, a positive baseline amyloid PET was associated with greater than twice the proportion of dementia conversions within the following three years.

Keywords: Alzheimer’s disease; amyloid PET; cerebrospinal fluid; conversion; longitudinal.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / cerebrospinal fluid
  • Alzheimer Disease / diagnostic imaging*
  • Alzheimer Disease / metabolism
  • Amyloid beta-Peptides / metabolism
  • Amyloidogenic Proteins / metabolism*
  • Aniline Compounds
  • Biomarkers / cerebrospinal fluid
  • Female
  • Fluorine Radioisotopes
  • France
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Peptide Fragments / metabolism
  • Positron-Emission Tomography / methods*
  • Prognosis
  • Stilbenes
  • tau Proteins / cerebrospinal fluid*

Substances

  • Amyloid beta-Peptides
  • Amyloidogenic Proteins
  • Aniline Compounds
  • Biomarkers
  • Fluorine Radioisotopes
  • Peptide Fragments
  • Stilbenes
  • tau Proteins
  • 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene